Daewoong Pharmaceutical Dividends and Buybacks
Dividend criteria checks 0/6
Daewoong Pharmaceutical is a dividend paying company with a current yield of 0.49%. Next payment date is on 14th April, 2025 with an ex-dividend date of 27th December, 2024.
Key information
0.5%
Dividend yield
0%
Buyback Yield
| Total Shareholder Yield | 0.5% |
| Future Dividend Yield | 0.5% |
| Dividend Growth | -1.0% |
| Next dividend pay date | 14 Apr 25 |
| Ex dividend date | 27 Dec 24 |
| Dividend per share | ₩600.000 |
| Payout ratio | 7% |
Recent dividend and buyback updates
Recent updates
Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)
Nov 22
There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price
Nov 06Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly
Oct 15Daewoong Pharmaceutical Co., Ltd (KRX:069620) Shares Could Be 49% Below Their Intrinsic Value Estimate
Aug 13Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings
Jul 24We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt
Jul 04Stability and Growth of Payments
Fetching dividends data
Stable Dividend: A069620 is not paying a notable dividend for the KR market, therefore no need to check if payments are stable.
Growing Dividend: A069620 is not paying a notable dividend for the KR market, therefore no need to check if payments are increasing.
Dividend Yield vs Market
| Daewoong Pharmaceutical Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (A069620) | 0.5% |
| Market Bottom 25% (KR) | 1.3% |
| Market Top 25% (KR) | 4.0% |
| Industry Average (Pharmaceuticals) | 1.1% |
| Analyst forecast (A069620) (up to 3 years) | 0.5% |
Notable Dividend: A069620's dividend (0.49%) isn’t notable compared to the bottom 25% of dividend payers in the KR market (1.26%).
High Dividend: A069620's dividend (0.49%) is low compared to the top 25% of dividend payers in the KR market (4.01%).
Earnings Payout to Shareholders
Earnings Coverage: A069620 is not paying a notable dividend for the KR market.
Cash Payout to Shareholders
Cash Flow Coverage: A069620 is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 12:40 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Daewoong Pharmaceutical Co., Ltd is covered by 26 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |
| Hyonseok Kim | CLSA |
| Heeyoung Lee | Daishin Securities Co. Ltd. |